Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Jagan R. Muppidi, MD PhD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Lydia L. Chou, CRNP, Sarah Evans, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134115

Published: 2020

Journal Articles

Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142633

Published: 2020

Journal Articles

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Ralph Mangusan, DNP, CRNP, Jomy George, PharmD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Mark Roth, MD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Vickie Ann Marshall, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137188

Published: 2020

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137637

Published: 2020

Journal Articles

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Michail S. Lionakis, MD ScD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137709

Published: 2020

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141447

Published: 2020

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Joo Y. Song, MD, Caoimhe Egan, Alyssa Bouska, PhD, Weiwei Zhang, PhD, Qiang Gong, Girish Venkataraman, MD MBBS, Alex F. Herrera, MD, Lu Chen, PhD, Rebecca Ottesen, Joyce Niland, PhD, Victoria Bedell, Maria Valle-Catuna, Joyce Murata-Collins, PhD, Dennis D. Weisenburger, MD, Javeed Iqbal, PhD, Elaine S. Jaffe, MD, Wing C. Chan, MD

Blood (2019) 134 (Supplement_1): 1486.

https://doi.org/10.1182/blood-2019-125095

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis

Christopher Melani, MD, Mark Roschewski, MD, Stefania Pittaluga, MD PhD, Jeffrey Cohen, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 785.

https://doi.org/10.1182/blood-2018-99-116707

Published: 2018

Journal Articles

Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

Christopher Melani, MD, Stefania Pittaluga, MD PhD, Lydia Yee, CRNP, Andrea Lucas, RN, Margaret Shovlin, RN, Allison Jacob, MS, Kenneth Chan, PhD, Marissa Vignali, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2017) 130 (Supplement 1): 2728.

https://doi.org/10.1182/blood.V130.Suppl_1.2728.2728

Published: 2017

Journal Articles

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Christopher Melani, MD, Ranjana H. Advani, MD, Mark Roschewski, MD, Kelsey M. Walters, BS, Clara C. Chen, MD, Lucia Barrato, MD, Mark A. Ahlman, MD, Milos D. Miljkovic, MD, Seth M. Steinberg, PhD, Margaret Shovlin, RN, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2017) 130 (Supplement 1): 2859.

https://doi.org/10.1182/blood.V130.Suppl_1.2859.2859

Published: 2017

Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers

Blood (2017) 130 (Supplement 1): 375.

https://doi.org/10.1182/blood.V130.Suppl_1.375.375

Published: 2017

Journal Articles

Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma

Blood (2017) 130 (Supplement 1): 39.

https://doi.org/10.1182/blood.V130.Suppl_1.39.39

Published: 2017

Journal Articles

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

Jenny Zhang, BSc, Anupama Reddy, PhD, Nicholas Davis, BSc, Andrea Moffitt, PhD, Cassandra Love, Alexander Waldrop, PhD, Sirpa Leppa, MD, Annika Pasanen, MD, Leo Meriranta, MS, Marja-Liisa Karjalainen-Lindsberg, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Anne Ortved Gang, Estrid Hogdall, PhD, Tayla Heavican, Waseem Lone, PhD, Javeed Iqbal, MSc, PhD, Guojie Li, PhD, So Young Kim, PhD, Jane Healy, MD PhD, Kristy L. Richards, MD PhD, Yuri Fedoriw, MD, Leon Bernal-Mizrachi, MD, Jean L. Koff, MD, Ashley D. Staton, MD, Christopher Flowers, MD, Ora Paltiel-Clarfield, Neta Goldschmidt, MD, Maria Calaminici, MD PhD, Andrew James Clear, BSc, John G. Gribben, MDDSc FMedSci, Evelyn Nguyen, Magdalena Czader, MD PhD, Sarah L. Ondrejka, MD, Angela Collie, MD PhD, Eric D. Hsi, MD, Eric Tse, MBBS, PhD FRCP, FRCPath, Rex Au-Yeung, Yok-Lam Kwong, Gopesh Srivastava, William Choi, MBBS,MRCP, Andrew M Evens, DO,MSc, Monika Pilichowska, MD PhD, Manju Sengar, MD DM, Nishitha Reddy, MD MSCI, MBBS, Shaoying Li, MD, Amy Chadburn, MD, Leo I. Gordon, MD, Elaine S. Jaffe, MD, Rachel Rempel, Tiffany Tzeng, Tushar Dave, Lanie Happ, Deepthi Rajagopalan, Jyotishka Datta, David Dunson, Sandeep Dave, MD

Blood (2017) 130 (Supplement 1): 37.

https://doi.org/10.1182/blood.V130.Suppl_1.37.37

Published: 2017

Journal Articles

Mutation Spectrum of Transformed Nodular Lymphocyte Predominant Hodgkin Lymphoma and Comparison with De Novo Diffuse Large B-Cell Lymphoma

Joo Y. Song, MD, Caoimhe Egan, Qiang Gong, PhD, Girish Venkataraman, MD MBBS, Alex F. Herrera, MD, Rebecca Ottesen, Joyce Niland, PhD, Dennis D. Weisenburger, MD, Elaine S. Jaffe, MD, Wing C Chan, MD

Blood (2017) 130 (Supplement 1): 1463.

https://doi.org/10.1182/blood.V130.Suppl_1.1463.1463

Published: 2017

Journal Articles

Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction

Daniela S Gerhard, PhD, Bruno Grande, B. Sc., Nicholas Griner, PhD, Corey Casper, MD, Sarah E. Gerdts, MPH, Abraham Omoding, MD, Jackson Orem, MD, Sam M Mbulaiteye, MD, Martin D. Ogwang, MD, Steven J. Reynolds, MD MPH, Kishor Bhatia, PhD, Leona Ayers, MD, John K Choi, MD, Charles G. Mullighan, MBBS, MSc, PhD, John T. Sandlund, MD, Thomas B. Alexander, MD MPH, Jeremy S. Abramson, MD, Thomas G. Gross, MD PhD, Ariela Noy, MD PhD, Jeffrey Bethony, PhD, Fabio Leal, MD, PhD, Timothy C Greiner, MS, MD, Elaine S. Jaffe, MD, Nancy Lee Harris, MD, Julie M. Gastier-Foster, PhD, Jay Bowen, MS, Benjamin Hanf, Roland Schmitz, PhD, Jean-Paul Martin, MD, Marie-Reine Martin, MD, John D. Irvin, MD PhD, Ellen Miller, MS, Patee Gesuwan, Leandro C. Hermida, Tanja M. Davidsen, PhD, Andrew J. Mungall, Yussanne Ma, PhD, Marco A. Marra, PhD, Ryan D. Morin, Louis M. Staudt, MD PhD

Blood (2016) 128 (22): 1760.

https://doi.org/10.1182/blood.V128.22.1760.1760

Published: 2016

Journal Articles

Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups

Jenny Zhang, Anupama Reddy, Cassandra Love, Andrea B. Moffitt, Deepthi Rajagopalan, Sirpa Leppä, Annika Pasanen, MD PhD, Leo Meriranta, MS, Marja-Liisa Karjalainen-Lindsberg, Peter H Norgaard, MD PhD, Mette Pederson, Anne Ortved Gang, Estrid Hogdall, Kristy L. Richards, PhD MD, Yuri D. Fedoriw, MD, Leon Bernal-Mizrachi, MD, Jean L. Koff, MD, Ashley D. Staton, MD, Christopher Flowers, MDMS, Ora Paltiel-Clarfield, Neta Goldschmidt, MD, Maria Calaminici, Andrew James Clear, John Gribben, Evelyn Nguyen, Magdalena Czader, MD PhD, Sarah Lynn Ondrejka, DO, Angela Collie, MD PhD, Eric D Hsi, MD, Rex au-Yeung, Kwong Yok-Lam, Wai Lap Choi, MD, Gopesh Srivastava, Andrew M Evens, DO, MSc, FACP, Monika Pilichowska, MD PhD, Manju Sengar, Nishitha Reddy, MD MSCI, MBBS, Shaoying Li, MD, Elaine S. Jaffe, MD, Tiffany Tzeng, Jyotishka Datta, David Dunson, Sandeep Dave, MD

Blood (2016) 128 (22): 1087.

https://doi.org/10.1182/blood.V128.22.1087.1087

Published: 2016

NARROW

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis

Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers

Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

Mutation Spectrum of Transformed Nodular Lymphocyte Predominant Hodgkin Lymphoma and Comparison with De Novo Diffuse Large B-Cell Lymphoma

Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction

Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only